ArticlePloS one2026
Which are the most valued HIV pre-exposure prophylaxis attributes? A discrete choice experiment among sexual and gender minorities in Peru.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is potential demand for pre-exposure prophylaxis (PrEP) in Peru; however, little is known about preferences towards PrEP modalities or the importance of PrEP attributes. Our research focused on which attributes most influence PrEP modalities choice among sexual and gender minorities (SGM). We also assessed how participants' preferences vary by recruitment strategy and population.
methodsWe conducted a discrete choice experiment (DCE) in three mutually exclusive groups: (1) Implementation PrEP Project (ImPrEP) participants; (2) Sexually transmitted infections (STI) clinic attendees; and (3) Online respondents via social media outreach. PrEP attributes assessed were presentation, frequency of use, healthcare provider, HIV testing frequency, side effects, and efficacy. For the DCE, each participant was presented with 12 pairs of options with mixed attribute levels and had to choose one option per pair. The data were analyzed using choice-based conjoint analysis, employing Hierarchical Bayes estimation techniques to derive individual-level utility scores.
resultsFrom June to October 2021, we recruited 2832 participants, with median age of 27 years (IQR = 22-33); 56.2% completed tertiary education; and 47.1% earned US$232 or less. In general, efficacy (27.5%, 95% CI 26.9-28.1), and frequency of use (21.3%, 95%CI 20.8-21.7) were the most important attributes, with the online respondents the highest importance on efficacy (31.9%, 95%CI 31.0-32.8). Concerned about potential side effects were more common among STI clinic attendees (17.5% [95%CI: 16.9-18.2]) and online respondents (18.8% [95%CI: 18.3-19.3]), while the ImPrEP participants placed the greatest importance on the frequency of use [26.7%, 95%CI 25.6-27.7].
conclusionsOverall, attributes such as efficacy and frequency of use were the most important PrEP attributes across the recruitment strategies; however, current ImPrEP participants placed more weight on frequency than the other groups. Our data may be helpful for future PrEP scale-up strategies, anticipating potential users concerns, and learning from current users.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.